Advanced search

Vol 12, No 2 (2021)
Guidelines / Expert consensus
Published online: 2021-11-30

open access

View PDF Download PDF file
Page views 3359
Article views/downloads 396
Get Citation

Connect on Social Media

Connect on Social Media

Diagnostic and therapeutic recommendations of the Polish Society of Haematologists and Transfusiologists and Polish Adult Leukemia Group-CLL for chronic lymphocytic leukemia in 2021

Iwona Hus12, Krzysztof Giannopoulos34, Krzysztof Jamroziak5, Jerzy Błoński6, Dariusz Wołowiec7, Jacek Roliński89, Piotr Smolewski10, Tadeusz Robak6
DOI: 10.5603/HCP.2021.0001
Hematology in Clinical Practice 2021;12(2):37-66.

Abstract

Chronic lymphocytic leukemia (CLL) is a disease of the elderly, with a median age at diagnosis of approximately 70 years. The natural course of the disease varies greatly, and patients with nonprogressive and asymptomatic leukemia do not require treatment. The results of CLL treatment have improved significantly in recent years, mainly due to the introduction of new, more effective drugs, including BCR inhibitors and BCL2 inhibitors. The new drugs are used continuously, while venetoclax in combination with anti-CD20 antibodies is used for 24 (rituximab) or 12 (obinutuzumab) months, depending on the type of antibody and line of therapy. The choice of treatment protocol should largely depend on the assessment of 17p deletion/TP53 mutation and immunoglobulin variable heavy chain (IGVH) mutation status, which correlate with a worse response to immunochemotherapy.

The role of immunochemotherapy, which until recently was the mainstay of CLL treatment, has now significantly decreased. In the first-line, it is recommended only in patients without 17p deletion/TP53 mutation, with mutated IGVH. Other patients should receive novel targeted therapies. However, at the time of the preparation of these recommendations, these therapies are not available in the firs-line of treatment in Poland. Novel targeted therapies play a major role in the treatment of refractory/relapsed CLL, and immunochemotherapy is recommended primarily in patients with a long-term response to first-line therapy.

In this article, we present an update of the guidelines for the diagnosis and treatment of CLL, including the treatment of autoimmune complications, as well as the prophylaxis and treatment of infections, developed by the Polish Society of Haematologists and Transfusiologists and PALG-CLL Working Group.

Keywords: chronic lymphocytic leukemiafludarabinecladribinebendamustinechlorambucilrituximabobinutuzumabibrutinibvenetoclaxacalabrutinibidelalisib\

Article available in PDF format

View PDF Download PDF file

References

  1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20): 2375–2390.
    CrossRefPubMed
  2. Cancer Stat Facts: NHL — Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). https://seer.cancer.gov/statfacts/html/cllsll.html (April 23, 2021).
  3. Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019; 94(11): 1266–1287.
    CrossRefPubMed
  4. Goldin LR, Slager SL, Caporaso NE. Familial chronic lymphocytic leukemia. Curr Opin Hematol. 2010; 17(4): 350–355.
    CrossRefPubMed
  5. Sud A, Chattopadhyay S, Thomsen H, et al. Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk. Blood. 2019; 134(12): 960–969.
    CrossRefPubMed
  6. Robak T. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukemia. Hematology. 2004; 9(5–6): 387–400.
    CrossRefPubMed
  7. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018; 131(25): 2745–2760.
    CrossRefPubMed
  8. Eichhorst B, Robak T, Montserrat E, et al. ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(1): 23–33.
    CrossRefPubMed
  9. Rawstron AC, Bennett FL, O'Connor SJM, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008; 359(6): 575–583.
    CrossRefPubMed
  10. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975; 46(2): 219–234.
    PubMed
  11. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981; 48(1): 198–206, doi: 10.1002/1097-0142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v.
    PubMed
  12. Rai KR. A critical analysis of staging in CLL. In: Gale RP, Rai KR. ed. Chronic lymphocytic leukemia: recent progress and future directions. Liss, New York 1987: 253–264.
  13. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000; 343(26): 1910–1916.
    CrossRefPubMed
  14. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010; 28(29): 4473–4479.
    CrossRefPubMed
  15. Hallek M, Fischer K, Fingerle-Rowson G, et al. International Group of Investigators, German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010; 376(9747): 1164–1174.
    CrossRefPubMed
  16. O'Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018; 131(17): 1910–1919.
    CrossRefPubMed
  17. Jones J, Mato A, Coutre S, et al. Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. Br J Haematol. 2018; 182(4): 504–512.
    CrossRefPubMed
  18. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018; 36(19): 1973–1980.
    CrossRefPubMed
  19. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019; 380(23): 2225–2236.
    CrossRefPubMed
  20. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999; 94(6): 1848–1854.
    PubMed
  21. Lin K, Sherrington PD, Dennis M, et al. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood. 2002; 100(4): 1404–1409.
    CrossRefPubMed
  22. Stilgenbauer S, Bullinger L, Lichter P, et al. German CLL Study Group (GCLLSG). Genetic and chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia. 2002; 16(6): 993–1007.
    CrossRefPubMed
  23. Kröber A, Bloehdorn J, Hafner S, et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol. 2006; 24(6): 969–975.
    CrossRefPubMed
  24. Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016; 127(2): 208–215.
    CrossRefPubMed
  25. Burger JA, Tedeschi A, Barr PM, et al. RESONATE-2 Investigators. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015; 373(25): 2425–2437.
    CrossRefPubMed
  26. Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019; 381(5): 432–443.
    CrossRefPubMed
  27. Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018; 379(26): 2517–2528.
    CrossRefPubMed
  28. Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019; 20(1): 43–56.
    CrossRefPubMed
  29. Ghia P, Rawstron A. Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments. Leukemia. 2018; 32(6): 1307–1316.
    CrossRefPubMed
  30. Böttcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012; 30(9): 980–988.
    CrossRefPubMed
  31. Kwok M, Rawstron AC, Varghese A, et al. Minimal residual disease is an independent predictor for 10-year survival in CLL. Blood. 2016; 128(24): 2770–2773.
    CrossRefPubMed
  32. Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018; 378(12): 1107–1120.
    CrossRefPubMed
  33. Kater AP, Kipps T, Eichhorst B, et al. Five-year analysis of Murano study demonstrates enduring undetectable minimal residual disease (uMRD) in a subset of relapsed/refractory chronic lymphocytic leukemia (R/R CLL) patients (pts) following fixed-duration venetoclax-rituximab (VenR) therapy (tx). Blood. 2020; 136(Suppl 1): 19–21.
    CrossRef
  34. Catovsky D, Else M, Richards S. Chlorambucil — still not bad: a reappraisal. Clin Lymphoma Myeloma Leuk. 2011; 11(Suppl 1): S2–S6.
    CrossRef
  35. Robak T, Blonski JZ, Jamroziak K, et al. A randomized, multicenter study (PALG CLL4/ML 21283) of maintenance treatment with rituximab versus observation after induction treatment with rituximab, cladribine, and cyclophosphamide (RCC) regimen in patients with progressive chronic lymphocytic leukemia: interim analysis. Blood. 2013; 122(21): 1640.
    CrossRef
  36. Dearden C, Wade R, Else M, et al. UK National Cancer Research Institute (NCRI), Haematological Oncology Clinical Studies Group, NCRI CLL Working Group. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood. 2008; 111(4): 1820–1826.
    CrossRefPubMed
  37. Aapro MS, Bohlius J, Cameron DA, et al. European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011; 47(1): 8–32.
    CrossRefPubMed
  38. Lukenbill J, Kalaycio M. Fludarabine: a review of the clear benefits and potential harms. Leuk Res. 2013; 37(9): 986–994.
    CrossRefPubMed
  39. Robak T, Błoński J, Skotnicki AB, et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG-CLL4 (ML21283) trial. Eur J Haematol. 2018; 100(5): 465–474.
    CrossRefPubMed
  40. Robak T, Jamroziak K, Gora-Tybor J, et al. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol. 2010; 28(11): 1863–1869.
    CrossRefPubMed
  41. Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010; 28(10): 1756–1765.
    CrossRefPubMed
  42. Robak T, Smolewski P, Cebula B, et al. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer. 2006; 107(7): 1542–1550.
    CrossRefPubMed
  43. Fisher K, Kramer P, Busch R, et al. German CLL Study Group. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011; 29(26): 3559–3566.
    CrossRefPubMed
  44. Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012; 30(26): 3209–3216.
    CrossRefPubMed
  45. Eichhorst B, Fink AM, Bahlo J, et al. international group of investigators, German CLL Study Group (GCLLSG). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016; 17(7): 928–942.
    CrossRefPubMed
  46. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014; 370(12): 1101–1110.
    CrossRefPubMed
  47. Goede V, Fischer K, Engelke A, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015; 29(7): 1602–1604.
    CrossRefPubMed
  48. Goede V, Fischer K, Dyer M, et al. Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study Study EHA Congress, 2018. Abstract S151.
  49. Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015; 385(9980): 1873–1883.
    CrossRef
  50. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369(1): 32–42.
    CrossRefPubMed
  51. Byrd JC, Brown JR, O'Brien S, et al. RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371(3): 213–223.
    CrossRefPubMed
  52. Byrd JC, Furman RR, Coutre SE, et al. Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib/II PCYC-1102 study. Clin Cancer Res. 2020; 26(15): 3918–3927.
    CrossRefPubMed
  53. Munir T, Brown JR, O'Brien S, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019; 94(12): 1353–1363.
    CrossRefPubMed
  54. Lin VS, Lew TE, Handunnetti SM, et al. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. Blood. 2020; 135(25): 2266–2270.
    CrossRefPubMed
  55. Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020; 34(3): 787–798.
    CrossRefPubMed
  56. Ghia P, Pluta A, Wach M, et al. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020; 38(25): 2849–2861.
    CrossRefPubMed
  57. Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020; 395(10232): 1278–1291.
    CrossRefPubMed
  58. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370: 997–1007.
    CrossRef
  59. Zinzani PL, Rambaldi A, Gaidano G, et al. Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. Leuk Res. 2019; 81: 88–94.
    CrossRefPubMed
  60. Flinn IW, Hillmen P, Montillo M, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018; 132(23): 2446–2455.
    CrossRefPubMed
  61. Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016; 374(4): 311–322.
    CrossRefPubMed
  62. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018; 36(19): 1973–1980.
    CrossRefPubMed
  63. Jones JA, Mato A, Wierda W, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018; 19(1): 65–75.
    CrossRef
  64. Al-Sawaf O, Zhang C, Robecht S, et al. Clonal dynamics after venetoclax-obinutuzumab therapy: novel insights from the randomized, phase 3 CLL14 trial. ASH, 2020. Abstract 127.
  65. Fischer K, Al-Sawaf O, Hallek M. Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2020; 2020(1): 357–362.
    CrossRefPubMed
  66. Dreger P, Schetelig J, Andersen N, et al. European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT). Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood. 2014; 124(26): 3841–3849.
    CrossRefPubMed
  67. Dreger P, Michallet M, Bosman P, et al. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. Bone Marrow Transplant. 2019; 54(1): 44–52.
    CrossRefPubMed
  68. Dreger P, Döhner H, Ritgen M, et al. German CLL Study Group. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010; 116(14): 2438–2447.
    CrossRefPubMed
  69. Shea T, Johnson J, Westervelt P, et al. Cancer and Leukemia Group B. Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. Biol Blood Marrow Transplant. 2011; 17(9): 1395–1403.
    CrossRefPubMed
  70. van Gelder M, de Wreede LC, Bornhäuser M, et al. Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2017; 52(3): 372–380.
    CrossRefPubMed
  71. Frey NV, Gill S, Hexner EO, et al. Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified t cells in relapsed chronic lymphocytic leukemia. J Clin Oncol. 2020; 38(25): 2862–2871.
    CrossRefPubMed
  72. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968; 16(5): 622–626.
    CrossRefPubMed
  73. Salvi F, Miller MD, Grilli A, et al. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc. 2008; 56(10): 1926–1931.
    CrossRefPubMed
  74. Hallek M. Therapy of chronic lymphocytic leukaemia. Best Pract Res Clin Haematol. 2010; 23(1): 85–96.
    CrossRefPubMed
  75. Wierda WG, Byrd JC, Abramson JS, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 4.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020; 18(2): 185–217.
    CrossRefPubMed
  76. Cuneo A, Follows G, Rigolin GM, et al. GIMEMA, European Research Initiative on CLL (ERIC) and UK CLL forum. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. Haematologica. 2018; 103(7): 1209–1217.
    CrossRefPubMed
  77. Langerbeins P, Busch R, Anheier N, et al. Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. Am J Hematol. 2014; 89(12): E239–E243.
    CrossRefPubMed
  78. Richter MN. Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia. Am J Pathol. 1928; 4(4): 285–292.7.
    PubMed
  79. Tsimberidou AM, Keating MJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer. 2005; 103(2): 216–228.
    CrossRefPubMed
  80. Bockorny B, Codreanu I, Dasanu CA. Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature. Br J Haematol. 2012; 156(1): 50–66.
    CrossRefPubMed
  81. Jamroziak K, Grzybowska-Izydorczyk O, Jesionek-Kupnicka D, et al. Poor prognosis of Hodgkin variant of Richter transformation in chronic lymphocytic leukemia treated with cladribine. Br J Haematol. 2012; 158(2): 286–288.
    CrossRefPubMed
  82. Chigrinova E, Rinaldi A, Kwee I, et al. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood. 2013; 122(15): 2673–2682.
    CrossRefPubMed
  83. Fabbri G, Khiabanian H, Holmes AB, et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med. 2013; 210(11): 2273–2288.
    CrossRefPubMed
  84. Rossi D, Spina V, Forconi F, et al. Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis. Int J Cancer. 2012; 130(12): 3006–3010.
    CrossRefPubMed
  85. Tsimberidou AM, O'Brien S, Khouri I, et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006; 24(15): 2343–2351.
    CrossRefPubMed
  86. Papajík T, Mysliveček M, Urbanová R, et al. 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation. Leuk Lymphoma. 2014; 55(2): 314–319.
    CrossRefPubMed
  87. Tsimberidou AM, O'Brien SM, Cortes JE, et al. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma. 2002; 43(4): 767–772.
    CrossRefPubMed
  88. Rogers KA, Huang Y, Ruppert AS, et al. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. Br J Haematol. 2018; 180(2): 259–266.
    CrossRefPubMed
  89. Jain N, Ferrajoli A, Basu S, et al. et al.. A phase II trial of nivolumab combined with ibrutinib for patients with Richter transformation [abstract]. Blood. 2018; 132(Suppl 1): 296.
  90. Younes A, Brody J, Carpio C, et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. Lancet Haematol. 2019; 6(2): e67–e78.
    CrossRefPubMed
  91. Ding W, LaPlant BR, Call TG, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017; 129(26): 3419–3427.
    CrossRefPubMed
  92. Cwynarski K, van Biezen A, de Wreede L, et al. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012; 30(18): 2211–2217.
    CrossRefPubMed
  93. Wang Y, Tschautscher MA, Rabe KG, et al. Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. Haematologica. 2020; 105(3): 765–773.
    CrossRefPubMed
  94. Tsimberidou AM, O'Brien S, Kantarjian HM, et al. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer. 2006; 107(6): 1294–1302.
    CrossRefPubMed
  95. Barcellini W, Capalbo S, Agostinelli RM, et al. GIMEMA Chronic Lymphocytic Leukemia Group. Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica. 2006; 91(12): 1689–1692.
    PubMed
  96. Zent CS, Kay N. Autoimmune complications in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol. 2010; 23(1): 47–59.
    CrossRef
  97. Dearden C, Wade R, Else M, et al. UK National Cancer Research Institute (NCRI), Haematological Oncology Clinical Studies Group, NCRI CLL Working Group. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood. 2008; 111(4): 1820–1826.
    CrossRefPubMed
  98. Lewis FB, Schwartz RS, Dameshek W. X-radiation and alkylating agents as possible "trigger" mechanisms in the autoimmune complications of malignant lymphophroliferative disease. Clin Exp Immunol. 1966; 1(1): 3–11.
    PubMed
  99. Montillo M, Tedeschi A, Leoni P. Recurrence of autoimmune thrombocytopenia after treatment with fludarabine in a patient with chronic lymphocytic leukemia. Leuk Lymphoma. 1994; 15(1–2): 187–188.
    CrossRefPubMed
  100. Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol. 1998; 16(5): 1885–1889.
    CrossRefPubMed
  101. Myint H, Copplestone JA, Orchard J, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol. 1995; 91(2): 341–344.
    CrossRefPubMed
  102. Rogers KA, Ruppert AS, Bingman A, et al. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. Leukemia. 2016; 30(2): 346–350.
    CrossRefPubMed
  103. Montillo M, O'Brien S, Tedeschi A, et al. Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study. Blood Cancer J. 2017; 7(2): e524.
    CrossRefPubMed
  104. Hampel PJ, Larson MC, Kabat B, et al. Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. Br J Haematol. 2018; 183(3): 421–427.
    CrossRefPubMed
  105. Davids MS, Hallek M, Wierda W, et al. Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia. Clin Cancer Res. 2018; 24(18): 4371–4379.
    CrossRefPubMed
  106. Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2008: 450–456.
    CrossRefPubMed
  107. Cortes J, O'Brien S, Loscertales J, et al. Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. Cancer. 2001; 92(8): 2016–2022, doi: 10.1002/1097-0142(20011015)92:8<2016::aid-cncr1539>3.0.co;2-e.
    PubMed
  108. D'Arena G, Laurenti L, Capalbo S, et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol. 2006; 81(8): 598–602.
    CrossRefPubMed
  109. Bowen DA, Call TG, Shanafelt TD, et al. Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. Leuk Lymphoma. 2010; 51(4): 620–627.
    CrossRefPubMed
  110. Kaufman M, Limaye SA, Driscoll N, et al. A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia. Leuk Lymphoma. 2009; 50(6): 892–899.
    CrossRefPubMed
  111. Robak T, Błasińska-Morawiec M, Krykowski E, et al. Autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia treated with 2-chlorodeoxyadenosine (cladribine). Eur J Haematol. 1997; 58(2): 109–113.
    CrossRefPubMed
  112. Quinquenel A, Willekens C, Dupuis J, et al. Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS). Am J Hematol. 2015; 90(3): 204–207.
    CrossRefPubMed
  113. Quinquenel A, Godet S, Dartigeas C, et al. Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group. Am J Hematol. 2019; 94(7): E183–E185.
    CrossRefPubMed
  114. Lacerda MP, Guedes NR, Yamakawa PE, et al. Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p). Ann Hematol. 2017; 96(9): 1577–1578.
    CrossRefPubMed
  115. Zent CS, Ding W, Schwager SM, et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol. 2008; 141(5): 615–621.
    CrossRefPubMed
  116. Visco C, Ruggeri M, Laura Evangelista M, et al. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood. 2008; 111(3): 1110–1116.
    CrossRefPubMed
  117. Kyasa MJ, Parrish RS, Schichman SA, et al. Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol. 2003; 74(1): 1–8.
    CrossRefPubMed
  118. Hamblin TJ, Oscier DG, Young BJ. Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol. 1986; 39(7): 713–716.
    CrossRefPubMed
  119. D'Arena G, Capalbo S, Laurenti L, et al. Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients. Eur J Haematol. 2010; 85(6): 502–507.
    CrossRefPubMed
  120. Rossignol J, Michallet AS, Oberic L, et al. Rituximab–cyclophosphamide–dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leukemia. 2011; 25(3): 473–478.
    CrossRefPubMed
  121. Cesana C, Carlo-Stella C, Mangoni L, et al. Response to cyclosporin A and recombinant human erythropoietin in a case of B cell chronic lymphocytic leukemia and pure red cell aplasia. Leukemia. 1996; 10(8): 1400–1401.
    PubMed
  122. Koehrer S, Keating MJ, Wierda WG. Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP. Leukemia. 2010; 24(5): 1096–1098.
    CrossRefPubMed
  123. Visco C, Rodeghiero F, Romano A, et al. Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study. Blood. 2019; 134(20): 1708–1711.
    CrossRefPubMed
  124. Paul S, Jain N, Ferrajoli A, et al. A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia. Br J Haematol. 2019; 185(3): 606–608.
    CrossRefPubMed
  125. Chikkappa G, Pasquale D, Zarrabi MH, et al. Cyclosporine and prednisone therapy for pure red cell aplasia in patients with chronic lymphocytic leukemia. Am J Hematol. 1992; 41(1): 5–12.
    CrossRefPubMed
  126. Ghazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood. 2002; 99(3): 1092–1094.
    CrossRefPubMed
  127. Abbott BL. Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. Oncologist. 2006; 11(1): 21–30.
    CrossRefPubMed
  128. Oscier D, Dearden C, Eren E, et al. British Committee for Standards in Haematology. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol. 2012; 159(5): 541–564.
    CrossRefPubMed
  129. Molica S. Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment. Leuk Lymphoma. 1994; 13(3-4): 203–214.
    CrossRefPubMed
  130. Quinquenel A, Aurran-Schleinitz T, Clavert A, et al. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO). Hemasphere. 2020; 4(5): e473.
    CrossRefPubMed
  131. Molteni A, Nosari A, Montillo M, et al. Multiple lines of chemotherapy are the main risk factor for severe infections in patients with chronic lymphocytic leukemia with febrile episodes. Haematologica. 2005; 90(8): 1145–1147.
    PubMed
  132. Morrison VA. Management of infectious complications in patients with chronic lymphocytic leukemia. Hematology. 2007; 2007(1): 332–338.
    CrossRef
  133. Rai KR, Keating MJ. Overview of the complications of chronic lymphocytic leukemia. https://www.uptodate.com/contents/overview-of-the-complications-of-chronic-lymphocytic-leukemia (March 30, 2021).
  134. Ye X, Xiao X, Li B, et al. Low humoral immune response and ineffective clearance of SARS-CoV-2 in a COVID-19 patient with CLL during a 69-day follow-up. Front Oncol. 2020; 10: 1272.
    CrossRefPubMed
  135. Kos I, Balensiefer B, Roth S, et al. Prolonged course of COVID-19-associated pneumonia in a B-cell depleted patient after rituximab. Front Oncol. 2020; 10: 1578.
    CrossRefPubMed
  136. Hammond SP, Chen K, Pandit A, et al. Risk of hepatitis B virus reactivation in patients treated with ibrutinib. Blood. 2018; 131(17): 1987–1989.
    CrossRefPubMed
  137. Pawłowska M, Flisiak R, Gil L, et al. Prophylaxis of hepatitis B virus (HBV) infection reactivation - recommendations of the Working Group for prevention of HBV reactivation. Clin Exp Hepatol. 2019; 5(3): 195–202.
    CrossRefPubMed
  138. Ryan CE, Cheng MP, Issa NC, et al. Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors. Blood Adv. 2020; 4(7): 1458–1463.
    CrossRefPubMed
  139. Ghez D, Calleja A, Protin C, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018; 131(17): 1955–1959.
    CrossRef
  140. Besa EC. Use of intravenous immunoglobulin in chronic lymphocytic leukemia. Am J Med. 1984; 76(3A): 209–218.
    CrossRefPubMed
  141. Griffiths H, Brennan V, Lea J, et al. Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood. 1989; 73(2): 366–368.
    PubMed
  142. Wasserman RL, Church JA, Peter HH, et al. IgPro10 in PID Study group. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. Eur J Pharm Sci. 2009; 37(3–4): 272–278.
    CrossRefPubMed
  143. Lucas M, Hugh-Jones K, Welby A, et al. Immunomodulatory therapy to achieve maximum efficacy: doses, monitoring, compliance, and self-infusion at home. J Clin Immunol. 2010; 30(Suppl 1): S84–S89.
    CrossRefPubMed
  144. Maarschalk-Ellerbroek LJ, Hoepelman IM, Ellerbroek PM. Immunoglobulin treatment in primary antibody deficiency. Int J Antimicrob Agents. 2011; 37(5): 396–404.
    CrossRefPubMed
  145. Provan D, Chapel HM, Sewell WA, et al. UK Immunoglobulin Expert Working Group. Prescribing intravenous immunoglobulin: summary of Department of Health guidelines. BMJ. 2008; 337: a1831.
    CrossRefPubMed
  146. Scarfò L, Chatzikonstantinou T, Rigolin GM, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020; 34(9): 2354–2363.
    CrossRefPubMed
  147. Hosoda T, Harada S, Okamoto K, et al. COVID-19 and fatal sepsis caused by hypervirulent klebsiella pneumoniae, Japan, 2020. Emerg Infect Dis. 2021; 27(2): 556–559.
    CrossRefPubMed
  148. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229): 1054–1062.
    CrossRefPubMed
  149. Griffiths H, Lea J, Bunch C, et al. Predictors of infection in chronic lymphocytic leukaemia (CLL). Clin Exp Immunol. 1992; 89(3): 374–377.
    CrossRefPubMed
  150. Sinisalo M, Aittoniemi J, Käyhty H, et al. Vaccination against infections in chronic lymphocytic leukemia. Leuk Lymphoma. 2003; 44(4): 649–652.
    CrossRefPubMed
  151. Sinisalo M, Vilpo J, Itälä M, et al. Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia. Vaccine. 2007; 26(1): 82–87.
    CrossRefPubMed
  152. Pollyea DA, Brown JMY, Horning SJ. Utility of influenza vaccination for oncology patients. J Clin Oncol. 2010; 28(14): 2481–2490.
    CrossRefPubMed
  153. Hartkamp A, Mulder AH, Rijkers GT, et al. Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. Vaccine. 2001; 19(13–14): 1671–1677.
    CrossRefPubMed
  154. de Lavallade H, Garland P, Sekine T, et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica. 2011; 96(2): 307–314.
    CrossRefPubMed
  155. Yri OE, Torfoss D, Hungnes O, et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood. 2011; 118(26): 6769–6771.
    CrossRefPubMed
  156. Garassino MC, Vyas M, de Vries EGE, et al. European Society for Medical Oncology. The ESMO call to action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate. Ann Oncol. 2021; 32(5): 579–581.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Hematology in Clinical Practice

About Via Medica Advertising
Bookstore (Ikamed) TVMed
News
Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice